Selectively targeting only cancer cells could help to avoid healthy cells and side effects from treatments.
A new study is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer.
A phase II study is the first to show that adding two targeted therapy drugs to the standard chemotherapy regimen is safe and effective as first-line treatment of advanced non-small cell lung cancer.
A small-molecule inhibitor of CDK 4/6 being developed showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies.
A highly targeted cancer radiation therapy may offer a safe and effective treatment option for elderly patients with pancreatic cancer who are unable to undergo surgery or combined chemotherapy and radiation therapy.
Substantial tumor regressions among some patients with advanced pancreatic cancer occurred in a recent clinical trial that paired the standard chemotherapy for pancreatic cancer, gemcitabine, with an agonist CD40 antibody.
The SHIVA trial is the first randomized trial to look at patient outcomes after treatments were chosen based on individual molecular profiles of each person's tumor.
Marked differences in the genomic terrain of the two most common types of cervical cancer suggest that patients might benefit from therapies geared to each type's molecular idiosyncrasies, according to a new study.
A specific protein has been found in nearly 100% of high-grade meningiomas, which is the most common form of brain tumor. This finding suggests a new target for therapies for a cancer that does not respond to current chemotherapy.
A newly discovered weakness in cancer cells may make them more susceptible to chemotherapy and other treatments.
In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.
Unique virus-derived particles have been developed that can kill human blood cancer cells in the laboratory and eradicate the disease in mice with few side effects.
A whole new class of drugs has been developed that targets the structure of the cancer cell for the first time.
Patients with diffuse large B-cell lymphoma, which often relapses and kills within 2 years, experienced a remission of their cancer and stayed disease-free as long as 28 months after taking a commercially available drug that made chemotherapy more effective.
Cellular therapy and gene therapy have been successfully combined in a mouse model to develop a viable treatment strategy for breast cancer that has spread to a patient's brain.
About 15% of patients with glioblastoma could receive personalized treatment with drugs currently used in other cancers, based on new research that has identified 18 genes responsible for driving glioblastoma multiforme.
An enzyme newly discovered to be overexpressed in some cases of triple-negative breast cancer (TNBC) represents a potential treatment target in this highly aggressive form of the disease.
The surprising discovery of an important functional link between the Myc oncogene and a regulator of protein synthesis control has finally provided scientists with a way to attack Myc-driven hematologic cancers.
When hypoxic and aggressive tumors were treated with an "oxygen challenge," tumor growth was delayed in an irradiated animal model. Measuring the oxygenation of tumors can be a valuable tool in guiding radiation therapy.
An abnormal metabolic pathway drives the growth of cancer cells in a particular glioblastoma subtype, according to new research.
A protein used by embryo cells during early development, and recently found in many different types of cancer, apparently serves as a switch regulating metastasis.
A drug approved in Europe to treat osteoporosis has been shown to stop the growth of breast cancer cells, according to a new study.
Novel abnormalities in the FGFR gene, called FGFR fusions, have been identified in a spectrum of cancers.
Tiny biosensors used with new advanced imaging techniques are markedly improving drug targeting of solid tumors, according to new research.
IN a recent study, colorectal tumors that had developed resistance to anti-epidermal growth factor receptor (anti-EGFR) therapies responded to drugs that block the action of the MET oncogene.
Sarcomatoid carcinomas may benefit from therapies targeting PD-1 protein and programmed death ligand-1 (PD-L1). PD-1 protein occurs in sarcomatoid carcinomas at higher levels than in other non-small cell lung cancers.
Adjuvant imatinib impacts short-term free from relapse in patients with localized, surgically resected, high/intermediate-risk gastrointestinal stromal tumors (GIST), according to interim results of an intergroup trial.
A new class of drugs targeting the genetic material of skin cancer has been successfully tested in humans for the first time. This opens the way to new treatments for a range of conditions from skin cancers to eye diseases.
The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to new results from a phase I study.
Combining a Wee1 protein inhibitor with the chemotherapy agent gemcitabine reduced sarcoma tumor volume more than did either drug alone.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|